XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.1
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
segment
Mar. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Number of reportable segments | segment     1        
Prepaid expenses and other current assets $ (34,769)   $ (34,769)   $ (6,851)    
Cash, cash equivalents and marketable securities 479,100   479,100   413,400    
Accumulated deficit (1,139,674)   (1,139,674)   (1,066,007)    
Net loss - basic and diluted (37,494) $ (22,851) (73,667) $ (94,898)      
Net income (loss) (37,494) (22,851) (73,667) (94,898)      
Cost of goods sold 1,042 0 2,023 0      
Inventory 4,397   $ 4,397   $ 121    
Customer Concentration Risk | Novartis Pharmaceutical | Accounts Receivable              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Concentration risk, percentage     30.00%   52.00%    
Customer Concentration Risk | Loxo Oncology | Accounts Receivable              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Concentration risk, percentage     0.00%   14.00%    
Customer Concentration Risk | Pierre Fabre | Accounts Receivable              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Concentration risk, percentage     14.00%   13.00%    
Customer Concentration Risk | McKesson Corporation | Accounts Receivable              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Concentration risk, percentage     11.00%   0.00%    
Accumulated Deficit              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Net income (loss) (37,494) $ (22,851) $ (73,667) $ (94,898) $ (147,300) $ (116,800) $ (92,800)
BRAFTOVI and MEKTOVI              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Inventory 11,300   11,300        
Pro Forma | BRAFTOVI and MEKTOVI              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Cost of goods sold $ 3,900   $ 4,600        
Reclassification              
Collaborative Arrangements and Non-collaborative Arrangements [Line Items]              
Prepaid expenses and other current assets         $ 100